In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Janssen-Cilag Ltd.

Division of Johnson & Johnson
www.janssen-cilag.co.uk

Latest From Janssen-Cilag Ltd.

Six New Drugs Get EMA Nod, Radius and Portola To Fight Rejections

Two products that the European Medicines Agency this week said should not be authorized for sale in the EU are already approved in the US.

Drug Review Approvals

Pipeline Watch: Phase III Starts In PTSD, Alzheimer’s Disease And Pancreatic Cancer

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

Gilead Gets CHMP Nod for New HIV Combo

Gilead has received the green light in the EU for marketing its newest fixed-dose HIV treatment Odefsey but its cannibalization of predecessor product Complera will not reach levels expected in the US as generic versions of older HIV combos are set to arrive earlier in the EU.

Infectious Diseases Europe

NICE Pans Pomalidomide For Blood Cancer, Backs Xarelto In ACS Patients

U.K. HTA rejects Celgene’s pomalidomide for treating multiple myeloma on cost grounds but waves through Bayer’s rivaroxaban for preventing blood clots in people who have had a heart attack.

BioPharmaceutical United Kingdom
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register